Jiwon Oh, MD, PhD, comments on potential risk factors that may increase a multiple sclerosis patient’s risk for acquiring coronavirus or complications of COVID-19 and discusses what is being done in clinical practice to reduce a patient’s risk during the pandemic.
Jiwon Oh, MD, PhD, discusses recent recommendations by the National Multiple Sclerosis Society on the use of disease-modifying therapies to treat MS during the coronavirus pandemic.
Implications for treating patients with multiple sclerosis with cladribine tablets based on long-term efficacy data revealed at the 2020 AAN Annual Meeting.
